Comparison of the effects of giving captopril and valsartan in cases of heart failure for people with congenital heart disease


Background: Congenital Heart Disease (CHD) has a prevalence ranging from 6 to 10 per 1000 live births, with an average of 8 out of 1000 live births. One of the pathological consequences of CHD is heart failure. Therapy for heart failure in CHD is still unsatisfactory. Purpose: Comparing the effect of captropyl and valsartan on clinical improvement, echocardiography, electrocardiography, and chest radiograph in cases of heart failure with congenital heart disease left to right. Method: The study design was Randomized Control Trial (RCT) by giving Double Blind Study treatment. There are 2 treatment groups, namely X1 by giving captopril and X2 by giving valsartan. Data were analyzed by Paired T-Test, T-Test, Mann-Whitney Test, and 5% significance. Result: The results of statistical analysis showed a significant change in the PHFS score, but it was not significant when compared between the two treatment groups. Increased LVEDV and LV dimension less after giving captopril than valsartan. There was an increase in LVEF after captopril administration although it was not significant when compared to the valsartan group. The reduction in CTR in the valsartan group was significant and the mean reduction in CTR in the valsartan group was greater than in the captopril group. Conclusion: Clinical, echocardiographic, electrocardiographic, and chest radiograph improvement after adding captopril and valsartan, but better improvements were obtained in valsartan administration than captopril.


  • Funabiki K., Onishi K. DK. Combined angiotensin receptor blocker and ace inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure. Am J Hear Circ Physiol. 2004;287:H2487-2492.
  • Anand, I. S., Fisher, L. D., Chiang, Y. T., Latini, R., Masson, S., Maggioni, A. P.,... & Cohn, J. N. (2003). Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation, 107(9), 1278-1283.
  • Aziz, A. S., Sigit, R., Basuki, A., & Hidayat, T. (2018). Cardiac motions classification on sequential PSAX echocardiogram. Indones. J. Electr. Eng. Comput. Sci., 12(3), 1289-1296.
  • Beggs, S., Thompson, A., Nash, R., Tompson, A., & Peterson, G. (2009). Cardiac failure in children. Proceedings of the 17th Expert Committee on the Selection and Use of Essential Medicines.
  • Bernstein, D (2007). Congenital heart disease. In: Behrman, Kliegman, Jenson, (eds.) Nelson Texbook of Pediatrics. 17th ed. Philadelphia: Saunders; 1499–1513 p.
  • Breathett, K., Allen, L. A., Udelson, J., Davis, G., & Bristow, M. (2016). Changes in left ventricular ejection fraction predict survival and hospitalization in heart failure with reduced ejection fraction. Circulation: Heart Failure, 9(10), e002962.
  • Buleshov, M. A., Buleshov, D. M., Yermakhanova, Z. A., Dauitov, T. B., Alipbekova, S. N., Tuktibayeva, S. A., & Buleshova, A. M. (2019). The choice of treatment for myocardial infarction based on individual cardiovascular risk and symptoms of coronary heart disease. Electronic Journal of General Medicine, 16(6), em183.
  • Delongchamp, R., Holt, A., Faramawi, M. F., Balamurugan, A., Reeve, G., Zohoori, N., & Bates, J. (2019). Differences between Arkansas and the United States in Prevalence of Risk Factors Explain Variations in Ischemic Heart Disease Mortality Rates among Pre-Medicare (45-64) and Medicare (65-84) Age Groups. European Journal of Environment and Public Health, 3(1), em0024.
  • Driscoll, D. J. (2006). Fundamentals of pediatric cardiology. Lippincott Williams & Wilkins.
  • Febry, Suci Suciati GI. Valsartan. In: Harry G. Brittain, editor (2015). Profiles of Drug Substances, Excipients, and Related Methodology. Academic Press, Elsevier Inc; 2015.
  • Flynn, J. T., Meyers, K. E., Neto, J. P., de Paula Meneses, R., Zurowska, A., Bagga, A.,... & Han, G. (2008). Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension, 52(2), 222-228.
  • Friedman, W. F. (1992). Congenital heart disease in infancy and childhood. Heart disease. A textbook of cardiovascular medicine, 906-908.
  • Kusumastuti, N. P., & Osaki, M. (2015). Electric velocimetry and transthoracic echocardiography for non-invasive cardiac output monitoring in children after cardiac surgery. Crit Care, 18(2), 37.
  • Marc, A. Pfeffer, J. J.V, Mcmurray, E.J, Velazquez, A.O (2003). Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med. 349(20):1893–906.
  • McMurray, J.J.V OJ& SK (2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (London, England).;362:767–71.
  • Park, M. K. (2008). Pediatric cardiology for Practitioners 5th ed Philadelphia: Mosby Elsevier. PLoS One, 166-175.
  • Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J.,... & Sharma, D. (2000). Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. The Lancet, 355(9215), 1582-1587.
  • Rosei, E. A., de Simone, G., Mureddu, G. F., Trimarco, B., Verdecchia, P., Volpe, M.,... & de Divitiis, O. (2008). Hypertensive heart disease: diagnostic and therapeutic guidelines. Giornale italiano di cardiologia (2006), 9(6), 427.
  • Rusgo, A. (2019). Follow-Up. Adult-Gerontology Acute Care Practice Guidelines, 60.
  • Tione, G., Edriss, A. K., Maonga, B., & Dzanja, J. (2018). Improved Potato Variety Analysis in Malawi: An Evaluation of Farmers Seed Demand. Canadian Journal of Agriculture and Crops, 3(2), 72-80.


This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.